BOCA RATON, Fla., Jan. 4 /PRNewswire/ -- Dawson James Securities, a full- service investment firm serving the healthcare and biotechnology industry, discussed the outlook for Biopure Corp. and Viragen, Inc. for 2007.
The interview with Stephen M. Dunn, Director of Research at Dawson James, included topics on Biopure such as the recent FDA Blood Products Advisory Committee vote on the U.S. Navy's clinical trial of Biopure's Hemopure in trauma patients. Mr. Dunn stated "I believe most of the media coverage was unduly fixated on the vote rather than the actual guidance from the Committee, which was in fact, quite positive. The very important favorable news was that the Committee felt Hemopure's benefits outweighed the risks but that a smaller 300-500 patient Phase II trial designed specifically for out-of-hospital trauma should be conducted. This now provides a regulatory pathway for Hemopure, which has been on clinical hold since June 2005."
Mr. Dunn also discussed Viragen which received regulatory approval for Multiferon in Sweden as a 1st-line treatment for malignant melanoma. He stated "It is possible that Multiferon could be sold in up to four of the largest European markets by the end of 2007 or early 2008. With almost 60,000 new malignant melanoma patients being diagnosed in Europe annually, Multiferon could provide significant benefit to thousands of patients."
The entire interview may be heard at http://www.ceocast.com/ with a direct link at http://www.ceocast.com/(ciq22g55fpaz3f30uw1gp5jx)/company.aspx?id=20314 Registration is free of charge.
About Dawson James Securities:
Dawson James Securities is a full service investment firm with deep expertise in healthcare and biotechnology and having a staff of over 50 investment professionals providing institutional research, investment banking and high net worth services to our clients. More information is available at http://www.dawsonjames.com/
Disclosures:
Dawson James has acted as an investment banker for the companies mentioned above and the Firm and/or its directors and employees may own securities in the companies and may increase or decrease holdings in the future.
The analyst certifies that 1) all of the views expressed accurately reflect his personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst; 3) the analyst responsible for preparing this research report receives compensation based upon various factors, including total revenues of Dawson James and its affiliates, a portion of which is generated by investment banking activities and 4) the analyst and/or members of their immediate family do not own stock in the companies mentioned.
Contact:
Dawson James Securities
Stephen M. Dunn, 561-208-2905
Fax: 561-391-5757
Dawson James Securities is a member of the National Association of Securities Dealers, CRD number 130645.
